Wenda Pharma reports Phase II trial results for BET inhibitor NHWD-870

Zhejiang Wenda Pharmaceutical Technology Co., Ltd. shared results from a Phase II clinical study of its candidate drug, NHWD-870 HCl, at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. The trial evaluated the efficacy and safety of the oral BET inhibitor in Chinese patients diagnosed with advanced NUT carcinoma, a rare and aggressive form of cancer.

The study highlights the drug's mechanism as a bromodomain and extra-terminal (BET) inhibitor, a class of therapeutics that targets epigenetic regulators to disrupt tumor progression. By presenting this data, Wenda Pharma aims to address a critical need in treating NUT carcinoma, which currently has limited standard-of-care options.

While the company has signaled positive trends in the patient data, the medical community will now assess these findings to determine the drug's potential role in future oncology treatment protocols. Wenda Pharma intends to use these trial results to inform subsequent regulatory discussions and clinical development milestones.